The type of therapy a cancer patient receives, largely depends on the trained eye of a pathologist.
Investigating diseased organs and tissues under the microscope is one of their tasks. However, human judgment is, by its very nature, subject to a certain degree of variation. To enhance the quality of diagnosis, scientists at Vetmeduni Vienna, the Medical University of Vienna and the Ludwig Boltzmann Institute for Cancer Research have developed a software that specifically identifies cell structures and proteins in order to provide reliable diagnoses. The scientists published their data in the journal Plos One.
Together with the company Tissuegnostics, the pathologist Lukas Kenner and his colleagues have developed a software that is able to identify cancer cells in tissue sections and demonstrate the presence of specific biomarkers on cells. The overall information provides a precise picture of the disease and leads to the most suitable treatment.
According to the results of the study, “Two independent pathologists concur with each other only in regard of every third diagnosis.”
“The recently developed software offers, for the first time, the option of eliminating the so-called inter-observer-variability, which is the systematic variability of judgement among different observers,” chief investigators Lukas Kenner and Helmut Dolznig explain.
Software identifies the severity of cancer
The Latest on: Diagnosis of cancer cells
via Google News
The Latest on: Diagnosis of cancer cells
- In the middle of a pandemic, a young Minnesota mother fights her second cancer diagnosison June 26, 2020 at 3:25 pm
Taylor Bustos said she'd never endure chemotherapy again. Less than a year later, she had to reckon with that promise.
- Basal cell carcinoma: Do you know how to spot this common type of skin cancer?on June 26, 2020 at 12:12 pm
With the COVID-19 pandemic, many of us are outdoors now more than ever. Take precautions to avoid basal cell carcinoma — and learn how to spot it.
- Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithmon June 25, 2020 at 10:27 pm
Path PD-L1 (SP263) image analysis uses automated pre-computing and one-click scoring to enable quicker and accurate detection and measurement of tumour cell staining.
- Leading Organizations Release Joint Clinical Guideline For Diagnosis And Evaluation Of Microhematuriaon June 25, 2020 at 6:55 pm
released the 2020 clinical guideline for the diagnosis, evaluation and follow-up of microhematuria. Microhematuria is short for microscopic hematuria and is when red blood cells can only be seen ...
- BriaCell Files Provisional Patent Application for Novel Treatment and Diagnosis of Coronavirus Diseaseon June 24, 2020 at 3:49 am
BERKELEY, Calif. and VANCOUVER, British Columbia, June 24, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) ...
- Signature of virus exposure may help detect liver canceron June 23, 2020 at 10:32 am
A blood test that measures people’s exposure to different viruses identified those who later developed liver cancer. The test could play an important role in improving outcomes for patients.
- Study: Menstrual Cups an Effective, More Comfortable Method of Diagnosis for Endometrial Canceron June 23, 2020 at 7:04 am
The researchers’ hypothesis had been that the endometrial cells collected by menstrual cups could allow for the screening of endometrial cancer. They also hypothesized ... During the study, the ...
- Thermo Fisher Scientific and Daiichi Sankyo to Co-Develop Global Companion Diagnostic for Patients with Non-Small Cell Lung Canceron June 23, 2020 at 4:00 am
Thermo Fisher Scientific and Daiichi Sankyo have expanded their partnership by signing a new agreement to co-develop a companion ...
- Nanostructured toxins for the selective destruction of drug-resistant human CXCR4style+ colorectal cancer stem cellson June 17, 2020 at 7:50 am
A novel toxin-based nanoparticle drug specifically is designed to attack colorectal cancer stem cells with overexpression of the chemokine receptor CXCR4.
- New Researches on CDK 4/6 Inhibitor Drugs Being Developed By Leading Companies For Early Diagnosis and Treatment Of Breast Cancer During 2020-2028on June 17, 2020 at 5:22 am
Research Nester released a report titled "CDK 4/6 Inhibitor Drugs Market: Global Demand Analysis & Opportunity ...
via Bing News